**Title page**

**Title: Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Study**

Mohammad Shehab,[1] MD FRCPC

Hajer Alasfour,[2] PharmD

Anwar Alhadab,[2] PharmD

Ghadeer Alhendi,[2] PharmD

Israa Abdullah,[2] PharmD

Ahmad Alfadhli,[1] MD FRCPC

Ali H. Ziyab,[3] MSc PhD

Robert Battat,[4] MD

1. Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Kuwait.
2. Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Kuwait.
3. Department of Community Medicine and Behavioral Sciences, Faculty of Medicine, Kuwait University, Kuwait.
4. Jill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, New York Presbyterian-Weill Cornell Medical College, New York, New York, USA

**Corresponding author:** Mohammad Shehab

Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah, Kuwait. Tel: (+965) 99633181. Email: dr_mshehab@hotmail.com.

**Acknowledgment:** To all the staff of the immunology department at Kuwait University.

**Declaration:** All authors declare no conflict of interest or financial support.

**Keywords:** IBD, TDM, ANTI-TNF, SEX, immunogenicity

**Summary:**

Anti-drug antibodies to infliximab (ATI) and adalimumab (ATA) are associated with loss of response to tumor necrosis factor antagonist (anti-TNF) therapy in inflammatory bowel disease (IBD). This study provides the first data from a large cohort of 1109 patients analyzing the impact of sex on immunogenicity rates. We found males have higher antibodies to infliximab than female patients and this effect was not seen with combination therapy. These differences were not observed for adalimumab.

**Abstract:**

**Introduction:**

Anti-drug antibodies to infliximab (ATI) and adalimumab (ATA) are associated with loss of response to tumor necrosis factor antagonist (anti-TNF) therapy in inflammatory bowel disease (IBD). We evaluated the relationship between patient sex and serum TNF antagonist drug and antibody concentrations in inflammatory bowel disease.

**Methods:**

A nationwide multicenter retrospective cohort study was conducted by evaluating patient charts from July 2018 until February 2021. The effect of patient sex on anti-drug antibodies and serum drug concentration in patients with IBD across 7 hospitals was investigated. A subgroup analysis also investigated the effect of anti-TNF combination therapy.

**Results:**

In the total study sample (n = 1093), males receiving infliximab had higher anti-drug antibody concentrations (38.3 vs. 22.3 AU/ml; aRoGM = 1.72, 95% CI: 1.30-2.27, p-value <0.001) compared to females. Additionally, infliximab serum drug concentrations among males were lower compared to females (2.6 vs. 4.1 ug/ml; aRoGM = 0.62, 95% CI: 0.44-0.88, p-value = 0.007). In the subgroup analysis (n = 359), male compared to female patients on combination therapy with infliximab and immunomodulators had similar anti-drug antibody concentrations (30.2 vs. 21.9 AU/ml; aRoGM = 1.38, 95% CI: 0.79-2.40, p-value = 0.254). . There was no difference in the anti-drug antibody and serum drug concentrations among males and females on adalimumab.

**Conclusion:**

In patients receiving infliximab, anti-drug antibodies were higher in males than females. Consistent with this, serum drug concentrations were lower in males than females on infliximab. However, there was no difference in anti-drug antibody and serum drug concentrations among males and females on adalimumab. In addition, no difference in anti-drug antibodies between males and females receiving anti-TNF combination therapy was observed.

**Introduction:**

Tumor necrosis factor antagonist (anti-TNF) therapies are commonly used for the management of moderate to severe inflammatory bowel disease (IBD) (1-3). However, an estimated one-third of patients treated with anti-TNF therapy are subjected to primary treatment failure (primary non-response) in which a lack of response is observed in induction therapy (4, 5). Moreover, approximately half of patients with initial response may experience secondary loss of response by losing treatment effect during the maintenance of remission (5). One of the most common causes of treatment failure is immunogenicity, the formation of anti-drug antibodies, which is also associated with low or undetectable drug serum concentrations (6, 7). The serum drug concentrations of anti-TNF therapy might also vary depending on the severity of disease, degree of inflammation, concurrent use of immunomodulator, patient sex, serum albumin concentration, body mass index, and genetic factors (5, 6).

Previous data show that anti-drug antibodies exist in over 20% of IBD patients treated with TNF antagonists (8). Additionally, patient sex significantly influences pharmacokinetics of infliximab. Clearance has been shown to be higher in male patients, and this effect increased in the presence of anti-drug antibodies and low serum albumin (9). On the other hand, combination therapy, the concurrent administration of an immunomodulator with an anti-TNF, has been associated with improvement in pharmacokinetics by decreasing immunogenicity and increasing serum drug concentrations (1-3). With respect to infliximab, the SONIC and UC-SUCCESS trials demonstrated that the use of infliximab combination therapy is superior to monotherapy in reducing immunogenicity and maintaining remission (10, 11). Conversely, DIAMOND trial and two other meta-analyses, by Kopylov et al. and Chalhoub et al., demonstrated that adalimumab combination therapy is associated with limited impact on maintenance of clinical remission or response (1, 12-14). However, large-scale real world studies with patient-level data are lacking on the relationship between patient sex and anti-TNF drug and anti-drug antibody concentrations. Additionally, the impact that combination therapy has on anti-TNF pharmacokinetics when accounting for sex has not been described. To address these knowledge gaps, this study utilized a large cohort with patient level data to determine the relationship between patient sex and immunogenicity of infliximab and adalimumab when accounting for important factors such as albumin and concomitant immunomodulator use.

**Methods**:

**Study design**:

A nationwide multicenter retrospective cohort study was conducted to measure the effect of patient sex on anti-TNF anti-drug antibodies and serum drug concentration in patients with inflammatory bowel disease (IBD). A subgroup analysis was performed at Mubarak Al-Kabeer Hospital, an inflammatory bowel disease center, for patients who received either infliximab or adalimumab monotherapy or in

combination with an immunomodulator. This study was performed and reported in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (15). The study protocol was reviewed and approved by the standing committee for coordination of health and medical research at the Ministry of Health in Kuwait (IRB 2020/1410).

We included patients that: (1) were previously diagnosed with inflammatory bowel disease (2) had been tested for an anti-drug antibody and/or serum drug trough level and (3) were receiving an anti-TNF therapy for at least 6 weeks at the time of measurement. The data were collected from patients' electronic medical records from all Kuwait's public hospitals (Mubarak al-Kabeer Hospital, Alamiri Hospital, Farwaniya Hospital, Aladan Hospital, Jahra Hospital, Alsabah Hospital, and Kuwait Oil Company Hospital). Data were collected from July 22nd, 2018 until Feb 7th, 2021. A subgroup analysis was performed at Mubarak Al-Kabeer Hospital, an inflammatory bowel disease center, for patients who received either infliximab or adalimumab combination or monotherapy.

**Definitions:**

Patients were considered to have active inflammation if they have one of the following: (1) C-reactive protein (CRP) levels above 10 mg/L and/or (2) actively receiving steroids. Patients were considered to be receiving steroids if they were concomitantly receiving budesonide, methylprednisolone, hydrocortisone, prednisone/prednisolone, or any steroidal agent. Also, patients who stopped taking steroids for less than 14 days from the day that serum drug concentration and antibodies were measured were also considered to be receiving steroids. Moreover, patients who received an immunomodulator (such as azathioprine, 6-mercaptopurine or methotrexate) concurrently with an anti-TNF therapy were classified to be on combination therapy while patients on infliximab or adalimumab alone were classified to be on monotherapy.

**Outcomes:**

The primary outcome was to compare anti-drug antibody levels between male and female patients on infliximab and adalimumab. In addition, the association between patient sex and serum drug concentration for infliximab and adalimumab was also evaluated.

Secondary outcomes, in sub-analyses, evaluated the impact of combination therapy among male and female patients on infliximab or adalimumab anti-drug antibody levels. The association between serum drug concentration and combination therapy in both sexes was estimated as well. Moreover, combination therapy was compared to monotherapy in terms of anti-drug antibody levels and serum drug concentration.

**Statistical analysis:**

Analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). The statistical significance level was set to $\alpha = 0.05$ for all association analyses. Descriptive analyses were conducted to calculate frequencies and proportions of categorical variables in the total study sample (n = 1093) and subsample (n = 359). To account for skewed distribution of continuous variables (i.e., age, serum drug concentrations, and anti-drug antibodies), geometric means were estimated by $\log_{10}$-transformation of the data and subsequently taking the antilog of the calculated means on the transformed scale (16). Correlations between anti-drug antibody and serum drug concentration according to anti-TNF drug type (infliximab and adalimumab) were assessed using Spearman correlation coefficients (r). In the total study sample analysis, the effect of patient sex on anti-drug antibody and serum drug concentrations of both adalimumab and infliximab were assessed. In the subsample analysis, the effect of patient sex on infliximab and adalimumab use in combination or alone on anti-drug antibody levels and serum drug concentrations were assessed.

Associations of adalimumab and infliximab with $\log_{10}$-transformed anti-drug antibody and serum drug concentration (outcome variables) were evaluated using multiple linear regression models. Associations were assessed in the total sample and stratified by sex. In the total sample analysis, associations were adjusted for the effects of sex, active inflammation, and age at assessment. In the subgroup analysis, associations were adjusted for sex, age at assessment, and active inflammation. In the sex stratified analysis, associations were adjusted for the effects of active inflammation and age at assessment. Given that we regressed $\log_{10}$-transformed anti-drug antibody and serum drug concentration, taking the antilog of the linear regression coefficients ($\beta$) yields adjusted ratio of geometric means (aRoGM), not the difference between geometric means. Hence, the related 95% confidence intervals (CIs) represent limits for RoGM with a null value of “1”.

Additional analyses were conducted to determine whether albumin can be a confounder of the assessed associations. Albumin was categorized as normal ($\geq$40 g/L) and abnormal (<40 g/L). The association of albumin (normal vs. abnormal) with anti-drug antibodies to infliximab and adalimumab were assessed by applying the Wilcoxon rank sum test. This analysis allowed us to determine whether concentrations of anti-drug antibodies differ across albumin categories. Moreover, albumin was added to the multiple linear regression models to determine if confounding is present.

**Results**:

**Demographics**:

In total, 1093 patients (567 [51.9%] males) were included in the total study sample analysis representing a total of 359 patients (187 [52.1%] males) were included in the per-patient analysis. The total study sample and the subsample were similar in all characteristics investigated. Of the total study sample, 42.2% of patients were on infliximab and 57.8% were on adalimumab. Similarly, in the subsample, 40.9% and 59.1% of patients were on infliximab and adalimumab, respectively (Table 1). Among patients in the subsample, 62.9% used anti-TNF combination therapy. Specifically, of the 147 patients on infliximab, 114 (77.6%) were on combination therapy while among the 212 patients on adalimumab, 112 (52.8%) were on combination therapy.

**Outcomes:**

Inter-sex comparisons of anti-drug antibody within anti-TNF therapy are shown in Table 2. Compared to female patients, male patients on infliximab had higher anti-drug antibody concentrations (38.3 vs. 22.3 AU/ml; aRoGM = 1.72, 95% CI: 1.30-2.27, p-value <0.001) (Figure 1a). However, male and female patients on infliximab combination therapy had similar anti-drug antibody levels (30.2 vs. 21.9 AU/ml; aRoGM = 1.38, 95% CI: 0.79-2.40, p-value = 0.254) (Figure 1b).

Male and female patients on adalimumab alone had similar anti-drug antibody levels (11.8 vs 13.7 AU/ml; aRoGM=0.86, 95% CI: 0.48-1.55, p-value=0.62). Males and females on adalimumab combination therapy had similar anti-drug antibody levels as well (13.5 vs 12 AU/ml; aRoM=1.13, 95% CI: 0.64-1.98, p-value=0.67, Table 2, Figure 1b).

Associations between anti-TNF therapy and serum drug concentrations are shown in Supplementary Table s1. In the total study sample, male patients had lower infliximab serum drug concentrations compared to female patients (2.6 vs. 4.1 ug/ml; aRoGM = 0.62, 95% CI: 0.44-0.88, p-value = 0.007). No other between sex differences in serum drug concentrations was observed (Supplementary Table s2). Serum drug concentrations were similar among patients on infliximab alone compared to those on infliximab combination therapy. Similarly, no difference in serum drug concentrations was observed among patients on adalimumab alone and those on adalimumab combination therapy (Supplementary Table s1).

Anti-drug antibody levels among patients on infliximab combination therapy were significantly lower than in patients on infliximab alone (25.7 vs. 50.8 AU/ml; aRoGM = 0.51, 95% CI: 0.28-0.91, p-value = 0.023). In addition, there was no different in anti-drug antibody between patients on adalimumab

combination therapy and those on adalimumab alone (12.7 vs. 12.7 AU/ml; aRoGM = 1.00, 95% CI: 0.66-1.51, p-value = 0.995; Supplementary Table s3).

In the total study sample, a negative correlation between infliximab serum concentration and anti-drug antibodies to infliximab (ATI) (spearman r = -0.388, p-value <0.001) and adalimumab serum concentration and anti-drug antibodies to adalimumab (ATA) (spearman r = -0.415; p-value <0.001; Figure 2) was observed. Associations between anti-TNF therapy (adalimumab and infliximab) and anti-drug antibody serum levels are shown in Supplementary Table s1. In the total study sample, subjects on infliximab had, on average, 2.40 times anti-drug antibody serum levels compared to those on adalimumab (29.2 vs. 12.2 AU/ml; aRoGM = 2.40, 95% CI: 1.99-2.89, p-value <0.001; Supplementary Table s3).

In an additional analysis, we assessed the association of albumin (≥40 g/L [normal] vs. <40 g/L [abnormal]) with anti-drug antibodies to infliximab and adalimumab. Comparing subjects with normal and abnormal albumin levels, we found that average levels of anti-drug antibodies to infliximab (10.6 vs. 19.2 AU/ml, p-value = 0.158) and anti-drug antibodies to adalimumab (7.5 vs. 7.4 AU/ml, p-value = 0.991) to be similar across categories of albumin. Moreover, when including albumin in the multiple regression models, the observed associations between male sex and higher anti-drug antibodies to infliximab and male sex and lower infliximab serum drug concentrations remained statistically significant. Hence, these additional analyses indicate that albumin does not confound the reported associations.

**Discussion:**

In 1109 patients with inflammatory bowel disease (IBD), we evaluated the effect of patient sex and combination therapy on anti-drug antibodies levels and serum drug concentrations among all patients who were on infliximab or adalimumab. The effect of the patient sex on the anti-drug antibodies levels was investigated in both monotherapy and combination therapy in our subgroup. The results of our study are similar to some studies that showed that serum drug concentrations of infliximab in male patients are commonly lower than female patients (5, 10). It is thought that male patients have higher clearance rates than female patients, however; the exact mechanism of this effect is still unknown (6, 7, 10). In addition, there is no previous available evidence, to our knowledge, that supports the association between patient sex and presence of anti-drug antibodies. On the other hand, the presence of higher anti-drug antibody levels seems to accelerate the clearance of anti-TNF therapy, which is supported by Fasanmade et al. study that analysed two randomized-controlled trials (17).

The available data on therapeutic drug response of patients with IBD to medications, stratified by sex, are extremely limited. A recent review by Rustgi et al. suggested the need for further investigation to the role of sex hormones on IBD, to get better therapeutic response for patients with IBD (18). Further studies might need to be done to identify if there is a genetic factor behind a correlation between the

patient sex and the anti-drug antibody levels. These further studies are needed because two previous studies, by Wilson et al. and Sazonovs et al., identified an association between the genetic variant HLA-DQA1*05 and the formation of anti-drug antibodies, against both infliximab and adalimumab, in patients with Crohn's disease (CD) (19, 20). A study by Sazonovs et al. showed that this variant increased the anti-drug antibodies formation by 2-folds, regardless of the concurrent immunomodulator use (20). They also concluded that to minimize the risk of therapy failure, a pretreatment genetic testing for HLA-DQA1*05 might be helpful in deciding whether to use anti-TNF, or combination therapy in IBD (19, 20).

As a secondary outcome of our study, the effect of combination therapy was investigated mainly in one inflammatory bowel disease center. The results of our study were similar to both SONIC and UC-SUCCESS trials in which the use of infliximab combination therapy lowered the rate of anti-drug antibodies (ATI) formation, resulted in higher serum drug concentrations, and better clinical outcomes (10, 11). Whereas for adalimumab combination therapy, our study results were also generally similar to the DIAMOND trial and to both Kopylov et al. and Chalhoub et al. meta-analyses (12-14). These studies did not show a superiority of combination therapy over adalimumab monotherapy in lowering the rate of anti-drug antibodies against adalimumab (ATA) formation. Furthermore, our study results do agree with Hazlewood et al. network meta-analysis where the comparison between the anti-TNF therapies revealed that combination therapy of infliximab with azathioprine and adalimumab monotherapy are the most effective therapies for inducing and maintaining clinical remission (21). Moreover, a systematic review, by Strand et al., emphasized the role of monitoring both anti-drug antibody levels and serum drug concentrations of the used anti-TNF agent (22). This might be potentially helpful in guiding clinicians to improve anti-TNF therapy management as well as clinical outcomes. Moreover, it can reduce risks associated with immunogenicity and can also help in lowering costs of therapy (22).

There were some limitations to our study. Being a retrospective cohort, there might be some confounders, which we tried to control for in our methods and analysis, such as inflammation and steroid use. Moreover, those on monotherapy could have been on combination therapy previously and then discontinued due to adequate serum drug concentration and low anti-drug antibodies. In addition, patients could have been on other medications for non IBD disease which theoretically could have affected our results.

**Conclusion:**

Anti-drug antibodies to infliximab (ATI) were higher in males than females whereas anti-drug antibodies to adalimumab (ATA) were similar in both sexes. In addition, male patients had lower infliximab serum drug concentrations compared to female patients while no sex differences was observed in adalimumab serum drug concentrations. Moreover, combination therapy was more effective than

monotherapy in reducing ATI, but not better than monotherapy in reducing ATA. However, male and female patients on infliximab combination therapy had similar anti-drug antibody levels.

**References:**


1. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 2019;14(1):4-22.
2. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's & colitis. 2017;11(7):769-84.
3. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450-61.
4. Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflammatory bowel diseases. 2017;23(9):1510-5.
5. Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and anti-drug Antibodies. Inflammatory bowel diseases. 2016;22(8):1999-2015.
6. Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therapeutic advances in gastroenterology. 2018;11:1756283x17750355.
7. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153(3):827-34.
8. Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, et al. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflammatory bowel diseases. 2020.
9. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Therapeutic drug monitoring. 2008;30(4):523-9.
10. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. The New England journal of medicine. 2010;362(15):1383-95.
11. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.e3.
12. Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. Journal of Crohn's & colitis. 2016;10(11):1259-66.

13. Kopylov U, Al-Taweel T, Yaghoobi M, Nauche B, Bitton A, Lakatos PL, et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. Journal of Crohn's & colitis. 2014;8(12):1632-41.
14. Chalhoub JM, Rimmani HH, Gumaste VV, Sharara AI. Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease. Inflammatory bowel diseases. 2017;23(8):1316-27.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453-7.
16. Bland JM, Altman DG. The use of transformation when comparing two means. BMJ (Clinical research ed). 1996;312(7039):1153.
17. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. European journal of clinical pharmacology. 2009;65(12):1211-28.
18. Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therapeutic advances in gastroenterology. 2020;13:1756284820915043.
19. Wilson A, Peel C, Wang Q, Pananos AD, Kim RB. HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2020;51(3):356-63.
20. Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology. 2020;158(1):189-99.
21. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology. 2015;148(2):344-54.e5; quiz e14-5.
22. Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2017;31(4):299-316.
23. World Health Organization (WHO). 2021. ”Health statistics and information systems: Definition of regional groupings”. Retrieved from: https://www.who.int/healthinfo/global_burden_disease/definition_regions/en/ on 7/5/2021.

**Tables:**

**Table 1.** Characteristics of total study sample and subsample with information on combination therapy use

| **Variable** | **Total study sample (n = 1093)** | **Subsample*** **(n = 359)** |
|---|---|---|
| **Age (years)** | | |
| Geometric mean (95% CI) | 25.2 (24.5 – 26.0) | 25.5 (24.3 – 26.8) |
| **Age group (n%)** | | |
| **≤16** | 198 (17.8%) | 61 (16.99%) |
| **17-40** | 728 (65.6%) | 238 (66.29%) |
| **>40** | 183 (16.5%) | 60 (16.71%) |
| **Sex, % (n)** | | |
| Male | 567 (51.9%) | 187 (52.1%) |
| Female | 526 (48.1%) | 172 (47.9%) |
| **Race, % (n)** | | |
| Middle East* | 1015 (91.5%) | 330 (91.9%) |
| Others | 94 (8.47%) | 29 (8.35%) |
| **Anti-TNF drug, % (n)** | | |
| Infliximab | 461(42.2%) | 147(40.9%) |

| | | |
|---|---|---|
| Adalimumab | 632 (57.8%) | 212 (59.15%) |
| **Infliximab serum concentration, (ug/ml)** | | |
| Geometric mean (95% CI) | 3.3 (2.7 – 4.1) | 2.3 (1.6 – 3.3) |
| Sample size, (n) | (461) | (147) |
| **Adalimumab serum concentration, (ug/ml)** | | |
| Geometric mean (95% CI) | 8.4 (7.4 – 9.5) | 8.4 (7.0 – 10.3) |
| Sample size, (n) | (565) | (201) |
| **Anti-Infliximab antibody serum levels, (AU/ml)** | | |
| Geometric mean (95% CI) | 29.0 (24.9 – 33.8) | 25.0 (18.8 – 33.2) |
| Sample size, (n) | (461) | (147) |
| **Anti-Adalimumab antibody serum levels, (AU/ml)** | | |
| Geometric mean (95% CI) | 12.2 (10.9 – 13.7) | 11.0 (9.2 – 13.1) |
| Sample size, (n) | (631) | (212) |
| **Active inflammation % (n)** | | |
| Yes | NA | 12.0 (43) |
| No | NA | 88.0 (314) |
| Missing, (n) | NA | (2) |
| **Anti TNF combination therapy use, % (n)** | | |

| | | |
|---|---|---|
| Yes | NA | 226 (62.9%) |
| No | NA | 133 (37.1%) |

CI: confidence interval; NA: data not available.

*Countries that are defined to be in the Middle East as per the World Health Organization (WHO) (23)

**Table 2.** Anti-drug antibody serum levels stratified by sex according to monotherapy and combination therapy for infliximab and adalimumab use: inter-sex comparisons

| | **Anti-drug antibody serum levels, Au/ml** | | | | | | |
|---|---|---|---|---|---|---|---|
| | **Males** | | | **Females** | | | |
| **Drug** | **n** | **Geometric mean (95% CI)** | | **n** | **Geometric mean (95% CI)** | **Ratio of geometric means* (95% CI) [M vs. F]** | **P-value** |
| *Total sample* | | | | | | | |
| Infliximab | 233 | 38.3 (31.4 – 46.6) | | 228 | 22.3 (18.2 – 27.2) | 1.72 (1.30 – 2.27) | < 0.001 |
| Adalimumab | 333 | 11.1 (9.4 – 13.1) | | 298 | 13.3 (11.2 – 15.9) | 0.84 (0.66 – 1.06) | 0.147 |
| *Subsample*† | | | | | | | |
| Infliximab | 14 | 106.5 (47.9 – 236.6) | | 19 | 24.2 (12.0 – 49.0) | 4.39 (1.58 – 12.25) | 0.005 |
| Infliximab + IM | 66 | 30.2 (20.0 – 45.6) | | 48 | 21.9 (13.8 – 34.9) | 1.38 (0.79 – 2.40) | 0.254 |
| Adalimumab | 47 | 11.8 (7.4 – 18.9) | | 53 | 13.7 (8.7 – 21.4) | 0.86 (0.48 – 1.55) | 0.621 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Adalimumab + IM | 60 | 13.5 (8.9 – 20.4) | | 52 | 12.0 (7.8 – 18.4) | 1.13 (0.64 – 1.98) | 0.677 |

CI: confidence interval; IM: immunomodulator; M: males; F: females.

* In the total sample, adjusted for sex and age at assessment. In the subsample, adjusted for sex, active inflammation, and age at assessment.

† Includes patients with information on immunomodulator use and active inflammation.

## Figure legends:

**Figure 1a. Anti-drug antibody levels in male and female patients with IBD in the total sample analysis for infliximab and adalimumab. The Y-axis corresponds to the geometric mean of the anti-drug antibodies serum levels.**

**Figure 1b. Anti-drug antibody serum levels in males and females with IBD in the subgroup analysis for Infliximab and Adalimumab. The Y-axis corresponds to the geometric mean of the anti-drug antibodies serum levels.**

**Figure 2. Spearman correlation coefficients (r) between anti-drug antibody levels and anti-TNF therapy serum drug concentration according to anti-TNF therapy in the total study sample. A) Spearman correlation coefficient between $log_{10}$-transformed infliximab serum concentration and $log_{10}$-transformed anti-infliximab antibody serum levels. B) Spearman correlation coefficient between $log_{10}$-transformed adalimumab serum concentration and $log_{10}$-transformed anti-adalimumab antibody serum levels.**


RoGM= 1.72
(P < 0.001)
RoGM= 0.84
(P 0.147)
45
40
35
30
25
20
15
10
5
0
Infliximab
Adalimumab
Anti-drug antibody serum levels, AU/mL Males
Anti-drug antibody serum levels, AU/mL Females




RoGM, Ratio of geometric mean


A
Log10 infliximab serum concentration
Spearman r = -0.388
P-value < 0.001
Number of pairs = 435
Log10 anti-infliximab antibody serum levels
B
Log10 adalimumab serum concentration
Spearman r = -0.415
P-value < 0.001
Number of pairs = 549
Log10 anti-adalimumab antibody serum levels